期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

厄洛替尼二线治疗化疗失败的晚期非小细胞肺癌的疗效 被引量：3

下载PDF
导出
摘要 目的观察厄洛替尼二线治疗化疗失败的晚期非小细胞肺癌(NSCLC)的近期疗效和毒副作用。方法 33例晚期NSCLC患者,每天口服150 mg厄洛替尼治疗,直到肿瘤进展或患者不能耐受时停止,观察近期疗效及毒副作用。结果 33例患者中无完全缓解(CR),部分缓解(PR)24.2%(8/33),稳定(SD)48.5%(16/33),进展(PD)27.3%(9/33),缓解(CR+PR)率为24.2%(8/33),疾病控制(CR+PR+SD)率为72.7%(24/33)。毒副作用主要为皮疹、腹泻和轻度肝功能损害,对症处理后均缓解。结论厄洛替尼治疗晚期NSCLC有一定的疗效,严重毒副作用少。
作者 万莉娟 陈颖兰 周建英 刘晖群 任剑
机构地区 江西省肿瘤医院内二科
出处 《实用临床医学（江西）》 CAS 2011年第6期23-24,共2页 Practical Clinical Medicine
关键词 厄洛替尼 晚期肺癌 非小细胞肺癌 分子靶向治疗
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Herbst R S, Heymach ] V, Lippman S M. Lung cancer[J]. N Engl .1 Med,2008,359(13) :1367-1380.
  • 2Feld R,Sridhar S S,Shepherd F A,et al. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review [J]. J Thorac Oncol,2006,1(4) :367-376.
  • 3吴一龙,蒋国梁,陆舜,等.中国肺癌临床指南[M].北京:人民卫生出版社,2007:73.
  • 4Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patient streated with erlotinib:quality of life anal- ysis of the National Cancer Institute o[ Canada Clinical Trials Group Study Br. 21 [J]. J Clin Oncol, 2006, 24 (24) : 3831- 3837.
  • 5周际昌.实用肿瘤内科学[M].北京：人民卫生出版社,1998.331.
  • 6陆舜,李子明,成柏君,虞永峰,廖美琳,叶云.厄洛替尼治疗复治晚期非小细胞肺癌的临床分析[J].中国癌症杂志,2007,17(9):711-715. 被引量：46
  • 7Salomon D S, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignan- cies[J]. Crit Rev Oncol Hematol, 1995,19(3) : 183-282.
  • 8Sridhar S S,Seymour L,Shepherd F A,et al. Inhibitors of epi- dermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer[J]. Lancet Oncol, 2003,4(7):397-406.
  • 9Perez Soler R,Chaehoua A, Hammond L A, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer[J]. J Clin Oncol, 2004, 22 (16) : 3238-3247.

二级参考文献10

  • 1Salomon DS,Brandt R,Ciardiello F,et al.Epidermal growth factor-related peptides and their receptors in human malignancies[J].Crit Rev Oncol Hematot,1995,19:183-232.
  • 2Fontanini G,De Laurentiis M,Vignati S,et al.Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage Ⅰ-Ⅲ A non-small cell lung cancer:amphiregulin and microvessel count are independent prognostic indicators of survival[f].Clin Cancer Res,1998,4:241-249.
  • 3Grunwald V,Hidalgo M.Developing inhibitors of the epidermal growth factor receptor for cancer treatment[J].J Natl Cancer Inst,2003,95:851-867.
  • 4Shepherd FA,Rodrigues J,Ciuleanu T,et al.Erlotinib in previously treated non-small cell lung cancer[J].N Engl J Med,2005,353:123-132.
  • 5Bezjak A,Shepherd F,Tu D,et al.Symptone response in non-small cell lung cancer (NSCLC) patients treated with erlotinib:quality of life analysis of the NCIC CTG BR.21 trial[C].ASCO,2005.
  • 6Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (the IDEAL Trial)[J].J Clin Oncol,2003,21:2237-2246.
  • 7Kris MG,Natale RB,Herbst RS,et al.Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer:a randomized trial[J].JAMA,2003,290:2149-2158.
  • 8Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib[J].N Engl J Med,2004.350(21):2129-2139.
  • 9Tsao MS,Sakurada A,Cutz JC,et al.Erlotinib in lung cancer-molecular and clinical predictors of outcome[J].N Engl J Med,2005,353:133-144.
  • 10Sridhar SS,Seymour L,Shepherd FA.Inhibitors of epidermal-growth-factor receptors:a review of clinical research with a focus on non-small cell lung cancer[J].Lancet Oncol,2003,4:397-406.

共引文献187

同被引文献49

  • 1宋耕,轩菡,王年飞,王小磊,许苗苗,陈振东.甲磺酸伊马替尼的临床应用研究[J].中华临床医师杂志（电子版）,2011,5(24):7348-7350. 被引量：7
  • 2Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy [ J ]. J Pharmacol Exp Ther,2005,315 ( 3 ) :971-979.
  • 3Breccia-M, Efficace F, Alimena GI Imatinib treatment in chronic myelogenous leukemia:what have we learned so far? [ J 3. Cancer Lett,2011,300(2) :115-121.
  • 4Frolov A, Chahwan S, Ochs M, et al. Response markers and them olecularm echanisms of action of Gleevec in gastrointestinal stromal tumors [ J ]. Mol Cancer Ther,2003,2 ( 8 ) :699-709.
  • 5Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma [ J ]. J Hepatol,2004,41 ( 5 ) :864-880.
  • 6Cartwright T,Richards DA, Boehm KA.Cancer of the pancreas:are we making progress? A review of studies in the US oncology research network[J].Cancer Control,2008,15(4):308-313.
  • 7Demetri GD,van Oosterom AT,Garrett CR,et al.Efficacy and safety of Sunitinib in patients with advanced gastrointestinal stromal turnout after failure of imatinib:a randomised controlled trial[J].The Lancet, 2006,368(9544): 1329-1338.
  • 8Motzer RJ,Hutson TE,Tomczak P,etal.Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[J].J Clin Oncol,2009,27(22): 3584-3590.
  • 9Bai H,Liu Q,Shi M,et al. Edotinib and gefitinib treatments of the lung cancer in an elderly patient result in gastrointestinal bleeding[J]. Pak J Med Sci,2013,29(5):1278 -1 279.
  • 10Serizawa M, Takahashi T, Yamamoto N, et al. Genomic ab- errations associated with erlotinib resistance in non-small cell lung cancer cells [ J ]. Anticancer Res, 2013,33 ( 12 ) : 5 223 - 5 233.

引证文献3

二级引证文献5

实用临床医学（江西）
2011年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部